Mar 20, 2024 · Nicox SA announced results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost in the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension have been published in the peer-reviewed journal American Journal of Ophthalmology.

Mar 3, 2024 · According to the company, NCX 470, a novel NO-donating bimatoprost eye drop, is currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

Jul 3, 2023 · Nicox has announced new data from a Phase III clinical trial investigating NCX 470 in patients with open-angle glaucoma or ocular hypertension. NCX 470 is a novel nitric oxide-donating bimatoprost being developed for lowering intraocular pressure (IOP).

Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Mar 5, 2025 · NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the IOP-lowering effects of NO and prostaglandin analogs (PGAs) and is designed to release bimatoprost and NO into the eye to lower IOP by 2 different pathways in patients with open-angle glaucoma or ocular hypertension.

Jul 1, 2021 · The objective with these two trials is to demonstrate statistically superior efficacy of once-daily dosed NCX 470 ophthalmic solution 0.1% over latanoprost ophthalmic solution 0.005% (first marketed as Xalatan), the most prescribed PGA in the U.S., for the lowering of IOP.

Oct 31, 2022 · “NCX 470 is the first non-combination product to demonstrate statistical non-inferiority, and numerically greater intraocular pressure reduction, compared to a prostaglandin analog in a pivotal trial,” he said in a statement.

NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research …

Dec 1, 2024 · To identify the optimal dose of NCX 470, a nitric oxide (NO)-donating bimatoprost, for comparison to latanoprost in a phase 3 trial for open-angle glaucoma (OAG) or ocular hypertension (OHTN) using an adaptive dose selection design.

Feb 27, 2025 · Eyes treated with NCX 470 0.1% are more likely to achieve lower intraocular pressure (IOP) and greater percent reductions in IOP than those treated with latanoprost 0.005%, according to research presented at the American Glaucoma Society’s annual meeting held in Washington, DC from February 26 to March 2, 2025.